Treatment with tacrolimus enhances alveolar bone formation and decreases osteoclast number in the maxillae: A histomorphometric and ultrastructural study in rats

Histology and Histopathology

Volumn 23, Issue 10, 2008, Pages 1177-1184

  Andia, Denise Carleto ^a   Nassar, Carlos Augusto ^a   Nassar, Patrícia Oehlmeyer ^a   Guimarães, Morgana Rodrigues ^a   Cerri, Paulo Sérgio ^a   Spolidorio, Luis Carlos ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Osteoblasts; Osteoclasts; Tacrolimus

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACTIVITY; MALE; MONOTHERAPY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; RAT; TISSUE STRUCTURE; TRABECULAR BONE; ANIMAL; BONE DEVELOPMENT; DRUG EFFECT; JAW DISEASE; MAXILLA; OSTEOLYSIS; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANIMALIA; RATTUS;

ALVEOLAR BONE LOSS; ANIMALS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MAXILLA; MAXILLARY DISEASES; MICROSCOPY, ELECTRON, TRANSMISSION; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; TIME FACTORS;

EID: 54449092924     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Aramburu J., Rao A. and Klee C.B. (2000). Calcineurin: from structure to function. Curr. Top. Cell. Regul. 36, 237-295.
2. Baron R. (1989). Molecular mechanisms of bone resorption by the osteoclast. Anat. Rec. 224, 317-324.
3. Bienemann K., Gudowius S. and Niehues T. (2007). Topical tacrolimus is effective against eczema in Wiskott-Aldrich Syndrome (WAS). Acta. Paediatr. 96, 312-314.
4. Caffier P.P., Harth W., Mayelzadeh B., Haupt H. and Sedlmaier B. (2007). Tacrolimus: A new option in therapy-resistant chronic external otitis. Laryngoscope 117, 1046-1052.
5. Cerri P.S. (2005). Osteoblasts engulf apoptotic bodies during alveolar bone formation in the rat maxilla. Anat. Rec. A. Discov. Mol. Cell. Evol. Biol. 286, 833-840.
6. Cvetkovic M., Mann G.N., Romero D.F., Liang X.G., Yanfei M., Jee W.S.S. and Epstein W.S. (1994). The deleterious effects of longterm cyclosporine A, cyclosporine G and FK506 on bone mineral metabolism in vivo. Transplantation. 57, 1231-1237.
7. Epstein S., Inzerillo A.M., Caminis J. and Zaidi M. (2003). Disorders associated with acute rapid and severe bone loss. J. Bone. Miner. Res. 18, 2083-2094.
8. Guimarães M.R., Nassar P.O., Andia D.C., Nassar C.A., Spolidorio D.M.P., Rossa Jr.C. and Spolidorio L.C. (2007). Protective effects of Tacrolimus, a calcineurin inhibitor, in experimental periodontitis in rats. Arch. Oral. Biol. 52, 882-888.
9. Hirotani H., Tuohy N.A., Woo J.T., Stern P.H. and Clipstone N.A. (2004). The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J. Biol. Chem. 279, 13984-13992.
10. Horslen S., Barr M.L., Christebseb L.L., Ettenger R. and Magee J.C. (2007). Pediatric transplantation in the United States, 1996-2005. Am. J. Transplant., 7, 1339-1358.
11. Huja S.S., Fernandez S.A., Hill K.J. and Li Y. (2006). Remodeling Dynamics in the Alveolar Process in Skeletally Mature Dogs. Anat. Rec. Discov. Mol. Cell. Evol. Biol. 288, 1243-1249.
12. Igarashi K., Hirotani H., Woo J.T. and Stern P.H. (2005). Cyclosporine and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. Bone 35, 47-56.
13. Jiang H., Takahara S., Takano Y., Li D., Kyo M., Valdivia L.A., Kokado Y., Ishibashi M. and Sonoda T. (1991). Effect of FK506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. Transplant. Proc. 23, 540-541.
14. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H. and Imanaka H. (1987). FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. 40, 1249-1255.
15. Koga T., Matsui Y., Asagiri M., Kodama T., de Crombrugghe B., Nakashima K. and Takayanagi H. (2005). NFAT and Osterix cooperatively regulate bone formation. Nat. Med. 11, 880-885.
16. Krueger G.G., Eichenfield L., Goodman J.J., Krafchik B.R., Carlin C.S., Pang M.L., Croy R., Holum M.E., Jaracz E., Sawamoto T. and Keirns J. (2007). Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. J. Drugs Dermatol. 6, 185-193.
17. Li S., Louis L.B. 4th., Kawaharada N., Yousem S. and Pham S. (2003). Intrathymic inoculation of donor bone marrow induces long-term acceptance of lung allografts. Ann. Thorac. Surg. 75, 257-263.
18. Mackie E.J. (2003). Osteoblasts: novel roles in orchestration of skeletal architecture. Int. J. Biochem. Cell Biol. 35, 1301-1305.
19. Marcen R., Caballero C., Pascual J., Teruel J.L., Tenorio M., Ocana J., Villafruela J.J., Burgos F.J., Fernandez A.M., Muriel A. and Ortuno J. (2006). Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation 81, 826-831.
20. Misawa Y., Kageyama T., Moriyama K., Kurihara S., Yagasaki H., Deguchi T., Ozawa H. and Sahara N. (2007). Effect of age on alveolar bone turnover adjacent to maxillary molar roots in male rats: A histomorphometric study. Arch. Oral. Biol. 52, 44-50.
21. Miyata S., Ohkubo Y. and Mutoh S. (2005). A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm. Res. 54, 1-9.
22. Murakami K., Fujii T., Yukawa N., Yoshifuji H., Kawabata D., Tanaka M., Usui T. and Minori T. (2007). Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Mod. Rheumatol. 17, 167-170.
23. Nassar C.A., Nassar P.O., Andia D.C., Guimarães M.R. and Spolidorio L.C. (2008). The effects of up to 240 days of tacrolimus therapy on the gingival tissues of rats - a morphological evaluation. Oral Dis. 14, 67-72.
24. Parfitt A.M. (1988). Bone histomorphometry: standardization of nomenclature, symbols and units (summary of proposed system). Bone 9, 67-69.
25. Sass D.A., Bowman A.R., Yuan Z., Ma Y., Jee W. and Epstein S. (1997). Alendronate prevents cyclosporin A-induced osteopenia in the rat. Bone 21, 65-70.
26. Scolapio J.S., De Arment J., Hurley D.L., Romano M., Harnois D. and Weigand S.D. (2003). Influence of tacrolimus and short-duration prednisone on bone mineral density following liver transplantation. J. Parenter. Enteral. Nutr. 27, 427-432.
27. Scott L.J., McKeage K., Keam S.J. and Plosker G.L. (2003). Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63, 1247-1297.
28. Spolidorio L.C., Spolidorio D.M. and Holzhausen M. (2004a). Effects of long-term cyclosporin therapy on the periodontium of rats. J. Periodont. Res. 39, 257-262.
29. Spolidorio L.C., Spolidorio D.M., Nassar P.O., Nassar C.A., Holzhausen M. and Almeida P.O. (2004b). Influence of age on combined effects of cyclosporin and nifedipine on rat alveolar bone. J. Periodontol. 75268-272.
30. Spolidorio L.C., Holzhausen M., Spolidorio D.M., Nassar C.A., Nassar P.O. and Muscara M.N. (2005). Cyclosporin but not tacrolimus significantly increases salivary cytokine contents in rats. J. Periodontol. 76, 1520-1525.
31. Spolidorio L.C., Nassar P.O., Nassar C.A., Spolidorio D.M. and Muscará M.N. (2007). Conversion of immunosuppressive monotherapy from cyclosporin-A to tacrolimus reverses bone loss in rats. Calcif. Tissue. Int. 81, 114-123.
32. Stempfle H.U., Werner C., Siebert U., Assum T., Wehr U., Rambeck W.A., Meiser B., Theisen K. and Gartner R. (2002). The role of Tacrolimus (FK506)-based immunosuppression of bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation. 73, 547-552.
33. Sun L., Blair H.C., Peng Y., Zaidi N., Adebanjo O.A., Wu X.B., Wu X.Y., Iqbal J., Epstein S., Abe E., Moonga B.S. and Zaidi M. (2005). Calcineurin regulates bone formation by the osteoblast. Proc. Natl. Acad. Sci. USA 102, 17130-17135.
34. Sun L., Peng Y., Zaidi N., Zhu L.L., Iqbal J., Yamoah K., Wang X., Liu P., Abe E., Moonga B.S., Epstein S. and Zaidi M. (2007). Evidence that calcineurin is required for the genesis of bone resorbing osteoclasts. Am. J. Physiol. Renal. Physiol. 292, F285-291.
35. Takayanagi H. (2005). Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83, 170-179.
36. Tamler R. and Epstein S. (2006). Nonsteroid immune modulators and bone disease. Ann. NY Acad. Sci. 1068, 284-296
37. Tang L., Ebara S., Kawasaki S., Wakabayashi S., Nikaido T. and Takaoka K. (2002). FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell. Biol. Int. 26, 75-84.
38. Taylor A.L., Watson C.J.E. and Bradley J.A. (2005). Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit. Rev. Oncol. Hematol. 56, 23-46.
39. Voggenreiter G., Assenmacher S., Kreuzfelder E., Wolf M., Kim M.R., Nast-Kolb D. and Schade F.U. (2000). Immunosuppression with FK506 increases bone induction in demineralized isogeneic and xenogeneic bone matrix in the rat. J. Bone Miner. Res. 15, 1825-1834.
40. Yoshikawa T., Nakajima H., Yamada E., Akahane M., Dohi Y., Ohgushi H., Tamai S. and Ichijima K. (2000). In vivo osteogenic capability of cultured allogenic bone in porous hydroxyapatite: immunosuppressive and osteogenic potential of FK506 in vivo. J. Bone. Miner. Res. 15, 1147-1157.
41. Yoshikawa T., Nakajima H., Toshimasa U., Takahiko K., Yasunori E., Tamura T., Nonomura A. and Takakura Y. (2005). In vitro bone formation induced y immunosuppressive agent Tacrolimus hydrate (FK506). Tissue Eng. 11, 609-617.